Consolidation strategies in ovarian cancer: Observations for future clinical trials

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 66-71

  Sabbatini, Paul ^a   Spriggs, David ^a   Aghajanian, Carol ^a   Hensley, Martee ^a   Tew, William ^a   Konner, Jason ^a   Bell McGuinn, Kathryn ^a   Juretzka, Margrit ^a   Iasonos, Alexia ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Clinical trials; Consolidation strategies; Ovarian cancer

Indexed keywords

BICALUTAMIDE; CANCER VACCINE; GOSERELIN; IMATINIB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER REGRESSION; CANCER STAGING; CLINICAL STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; REMISSION INDUCTION;

EID: 70949093173     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.016     Document Type: Article

References (22)

1. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
2. Dizon D.S., Hensley M.L., Poynor E.A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J. Clin. Oncol. 20 (2002) 1238-1247
3. Markman M., Markman J., Webster K., et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J. Clin. Oncol. 22 (2004) 3120-3125
4. Hall G.D., Brown J.M., Coleman R.E., et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br. J. Cancer 91 (2004) 621-626
5. Alberts D.S., Hannigan E.V., Liu P.Y., et al. Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecol. Oncol. 100 1 (2006) 133-138
6. Schilder R.J., Brady M.F., Spriggs D., and Shea T. Pilot evaluation of high-dose carboplatin and paclitaxel followed by high-dose melphalan supported by peripheral blood stem cells in previously untreated advanced ovarian cancer: a gynecologic oncology group study. Gynecol. Oncol. 88 (2003) 3-8
7. Lambert H.E., Rustin G.J., Gregory W.M., and Nelstrop A.E. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J. Clin. Oncol. 11 (1993) 440-448
8. Sorbe B. Consolidation treatment of advanced ovarian carcinoma with radiotherapy after induction chemotherapy. Int. J. Gynecol. Cancer 13 Suppl 2 (2003) 192-195
9. Varia M.A., Stehman F.B., Bundy B.N., et al. Intraperitoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 (2003) 2849-2855
10. Nicoletto M.O., Tumolo S., Falci C., et al. A randomized study of epithelial ovarian cancer: is chemotherapy useful after complete remission?. Int. J. Med. Sci. 1 (2004) 116-125
11. De Placido S., Scambia G., Di Vagno G., et al. Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. J. Clin. Oncol. 22 (2004) 2635-2642
12. Berek J.S., Taylor P.T., Gordon A., et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J. Clin. Oncol. 22 (2004) 3507-3516
13. Sabbatini P., and Spriggs D.R. Consolidation for ovarian cancer in remission. J. Clin. Oncol. 24 (2006) 537-539
14. Harrison M.L., Gore M.E., Spriggs D., et al. Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol. Oncol. 106 (2007) 469-475
15. Juretzka M., Hensley M., Tew W., et al. A phase of oral imatinib in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma in second or greater remission. Eur J Gynaecol Oncol 29 6 (2008) 568-572
16. Levine D., Park K., Juretzka M., et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 110 (2007) 2448-2456
17. Sabbatini P.J., Ragupathi G., Hood C., et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 13 (2007) 4170-4177
18. Rustin G.J., Nelstrop A.E., Tuxen M.K., and Lambert H.E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann. Oncol. 7 (1996) 361-364
19. O'Quigley J., and Stare J. Proportional hazards models with frailties and random effects. Stat. Med. 21 (2002) 3219-3233
20. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
21. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J. Clin. Oncol. 24 (2006) 4699-4707
22. Panageas K.S., Ben-Porat L., Dickler M.N., Chapman P.B., and Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J. Natl. Cancer Inst. 99 (2007) 428-432